Management of Bone Disease and Body Composition Changes
Summary
- Tenofovir AF a novel prodrug of tenofovir that results in lower plasma concentrations and higher intracellular concentrations of tenofovir relative to tenofovir DF[Ruane 2013]
- Tenofovir AF has superior antiviral efficacy through 144 weeks and reduced bone toxicity when compared with tenofovir DF[Sax 2015; Arribas 2017]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Bone Disease , Treatment Complications